Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Epigenome editing

Nature Biotechnology volume 31, pages 1097–1099 (2013)Cite this article

Subjects

Technologies developed for genome editing are repurposed to study functions of chromatin modifications.

Genome-scale epigenetic maps have been generated for many different cell types and organisms and have yielded important biological insights, but such data are largely correlative. A crucial challenge in epigenetics is determining the precise roles of specific DNA or histone modifications. Two studies in this issue1,2 and one published recently in Nature3 show that epigenetic marks can be modified at a specific genomic locus, enabling fine-grained study of their activity. All three groups achieve this long-awaited goal using customizable transcription activator–like effector (TALE) proteins4—previously applied to editing the genome—to recruit chromatin-modifying enzymes to specific loci. These studies introduce powerful new tools to activate or repress specific genes and, perhaps more importantly, to analyze directly how individual chromatin modifications control chromatin states and gene expression.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Site-specific recruitment of chromatin modifiers for epigenome editing.

References

  1. Maeder, M.L. et al. Nat. Biotechnol. 31, 1127–1132 (2013).

    Article  Google Scholar 

  2. Mendenhall, E.M. et al. Nat. Biotechnol. 31, 1133–1138 (2013).

    Article  CAS  Google Scholar 

  3. Konermann, S. et al. Nature 500, 472–476 (2013).

    Article  CAS  Google Scholar 

  4. Joung, J.K. & Sander, J.D. Nat. Rev. Mol. Cell Biol. 14, 49–55 (2013).

    Article  CAS  Google Scholar 

  5. Gaj, T., Gersbach, C.A. & Barbas, C.F. Trends Biotechnol. 31, 397–405 (2013).

    Article  CAS  Google Scholar 

  6. Wiedenheft, B., Sternberg, S.H. & Doudna, J.A. Nature 482, 331–338 (2012).

    Article  CAS  Google Scholar 

  7. Jones, P.A. Nat. Rev. Genet. 13, 484–492 (2012).

    Article  CAS  Google Scholar 

  8. Williams, K., Christensen, J. & Helin, K. EMBO Rep. 13, 28–35 (2012).

    Article  CAS  Google Scholar 

  9. Calo, E. & Wysocka, J. Mol. Cell 49, 825–837 (2013).

    Article  CAS  Google Scholar 

  10. Mosammaparast, N. & Shi, Y. Annu. Rev. Biochem. 79, 155–179 (2010).

    Article  CAS  Google Scholar 

  11. Kennedy, M.J. et al. Nat. Methods 7, 973–975 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry and Molecular Pharmacology New York University School of Medicine, Philipp Voigt & Danny Reinberg are at the Howard Hughes Medical Institute, New York, New York, USA.,

    Philipp Voigt & Danny Reinberg

Authors
  1. Philipp Voigt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Danny Reinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Danny Reinberg.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Voigt, P., Reinberg, D. Epigenome editing. Nat Biotechnol 31, 1097–1099 (2013). https://doi.org/10.1038/nbt.2756

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2756

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research